No Data
No Data
Express News | Shanghai Kehua Bio-Engineering: HIV-1 nucleic acid testing kit (PCR-fluorescence probe method) has obtained a registration certificate for medical instruments.
Shanghai Kehua Bio-Engineering (002022.SZ): Both the company's self-produced products and agent products adopt a sales model mainly based on distribution and supplemented by direct sales.
Shanghai Kehua Bio-Engineering (002022.SZ) stated on the investor platform that the company adopts a sales model which focuses on dealers while also utilizing direct sales for both self-produced and third-party products. In order to adapt to the development trend of the in-vitro diagnostic industry and in consideration of the structural characteristics of in-vitro diagnostic products, the company has built an extensive network of dealers both domestically and abroad, and possesses a professional marketing team and a sound marketing system. The company does not currently have a store on any e-commerce platform.
Kehua's Energy Storage Solution Propels Bulgaria's Largest BESS Project
Shanghai Kehua Bio-engineering: 2024 Interim Performance Forecast
Express News | Shanghai Kehua Bio-Engineering: It is expected to have a net loss of 400-570 million yuan in the first half of the year.
Kehua Bio-Engineering Gets Nod to Register Two Medical Devices
No Data